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Abstract
Objective: Candidate genes for non-alcoholic fatty liver disease (NAFLD) identified by a bioinformatics approach were
examined for variant associations to quantitative traits of NAFLD-related phenotypes.
Research Design and Methods: By integrating public database text mining, trans-organism protein-protein interaction
transferal, and information on liver protein expression a protein-protein interaction network was constructed and from this
a smaller isolated interactome was identified. Five genes from this interactome were selected for genetic analysis. Twenty-
one tag single-nucleotide polymorphisms (SNPs) which captured all common variation in these genes were genotyped in
10,196 Danes, and analyzed for association with NAFLD-related quantitative traits, type 2 diabetes (T2D), central obesity,
and WHO-defined metabolic syndrome (MetS).
Results: 273 genes were included in the protein-protein interaction analysis and EHHADH, ECHS1, HADHA, HADHB, and
ACADL were selected for further examination. A total of 10 nominal statistical significant associations (P,0.05) to
quantitative metabolic traits were identified. Also, the case-control study showed associations between variation in the five
genes and T2D, central obesity, and MetS, respectively. Bonferroni adjustments for multiple testing negated all associations.
Conclusions: Using a bioinformatics approach we identified five candidate genes for NAFLD. However, we failed to provide
evidence of associations with major effects between SNPs in these five genes and NAFLD-related quantitative traits, T2D,
central obesity, and MetS.
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Introduction
It has been estimated that around 20% of all adults have non-
alcoholic fatty liver disease (NAFLD) [1,2], which is defined by
accumulation of fat in hepatocytes exceeding 5-10% of the liver
weight [3]. In the obese adult population NAFLD is present
among 60% [1,2]. NAFLD associates with insulin resistance and
type 2 diabetes (T2D) and it has been suggested that it might
predict the presence or future development of the metabolic
syndrome (MetS) [4,5]. While environmental factors causing
NAFLD are well-known [3,6], it has been suggested that genetics
factors also predispose to NAFLD [7,8] and that these might
explain the difference in NAFLD progression between individuals
[7,9].
At the biochemical level NAFLD often presents with abnormal
liver enzymes without the presence of markers of other common
liver disease, e.g., hepatitis C [10]. Non-invasive tests such as the
BAAT (body mass index, age, alanine aminotransferase, triglyc-
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16542erides), the European liver fibrosis score, Fibrotest, Fibroscan,
hyaluronic acid, BARD (body mass index, aspartate aminotrans-
ferase (AST):alanine aminotransferase (ALT), diabetes), non-
alcoholic steatohepatitis (NASH) score, and the NAFLD fibrosis
score have been developed [11], and have all been tested in
individuals with NAFLD [10]. However, these tests are still
insufficient to replace liver biopsy [10], which currently is the gold
standard for the diagnosis and assessment of severity of NAFLD
[3]. Nevertheless, knowledge of MetS, T2D, serum insulin, AST,
and ALT concentrations has in a study by Kotronen et al. allowed
prediction of NAFLD with a sensitivity of 86% and a specificity of
71% [12].
Several genes have been suggested as putative candidate genes
for NAFLD susceptibility or progression of the disease [7].
Recently, genome-wide association (GWA) studies have success-
fully contributed to the gene discovery process by identifying
common genetic variants in several complex human diseases
including NAFLD. In a GWA study of liver fat content in 2,111
individuals of different ancestry, the G-allele of rs738409 in
patatin-like phospholipase domain containing 3 (PNPLA3) showed
strong evidence of association with NAFLD [13]. Additionally,
PNPLA3 was found to be associated with ALT concentration in a
GWA of plasma liver-enzyme levels in a Caucasian population
[14]. However, addition of information of variation in PNPLA3 did
not significantly improve the NAFLD prediction score [12].
Bioinformatics is often used in the investigation, establishment,
and ranking of biological candidate genes, and e.g., protein-
protein interaction analyses can be used to identify disease-related
complexes [15]. This method places the potential disease-causing
proteins in a functional context, relative to other known or
unknown disease-associated proteins, and thus, systematic inves-
tigation of such complexes might unmask new candidate genes for
NAFLD-related phenotypes.
The objective of the present study was to identify new putative
candidate genes for NAFLD-associated phenotypes using a
bioinformatics approach that implements text mining, trans-
organism protein-protein interaction transferal, and publicly
available information on protein expression levels in the liver.
Furthermore, we investigated the association of common genetic
variants in the candidate genes with NAFLD-related quantitative
traits (waist circumference, serum triglyceride, and fasting levels of
serum insulin and plasma glucose) in 6,162 middle-aged Danes.
Also, case-control analyses were performed using a total of 10,196
middle-aged Danes to investigate putative associations between
the genetic variants and T2D, central obesity, and MetS.
Materials and Methods
The studies were approved by the Ethical Committee of
Copenhagen and were in accordance with the principles of the
Declaration of Helsinki II. Informed written consent was obtained
from all individuals before participation.
Selection of candidate genes using a bioinformatics
approach
We used text mining in NCBI Databases (build 36) as the initial
approach to identify potential biological candidate genes. This
consisted of two PubMed searches using the search terms
‘‘(‘‘hepatic steatosis’’ OR ‘‘NAFLD’’) AND genes’’, or ‘‘(‘‘visceral
obesity’’ OR ‘‘waist circumference’’) AND genes’’. Limits: only
within year 2003–2008 that reduces the search results with app.
50%. All results were reviewed manually. Only papers published
in English were considered. Full texts of papers were searched
when accessible. Also, we searched the online mendelian
inheritance in man (OMIM) for genetic abnormalities leading to
syndromes with fatty liver related phenotypes, and for the terms
‘‘(‘‘hepatic steatosis’’ OR ‘‘NAFLD’’) AND genes’’, or ‘‘(‘‘visceral
obesity’’ OR ‘‘waist circumference’’) AND genes’’. Text mining
identified 273 genes putatively implicated in NAFLD, and these
were prioritized according to how often they were co-mentioned
with the terms ‘‘fatty liver’’ or ‘‘NAFLD’’ in the literature. Of the
273 genes we removed 26 genes due to gene symbol overlap,
missing human homologue or missing ensembl ID. The 247
remaining biological candidate genes were then prioritized using a
scoring scheme based on the origin of the data and OMIM
phenotypes (Supporting Information S1). 37 biological candidate
genes had a priority score .2 (Supporting Information S1) and
were selected for further bioinformatics analysis according to: 1)
MeSH terms (using the GeneCard database (www.genecards.org)),
2) keywords (using the AKS2 database (www.bioalma.com/aks2/
index.php)), 3) pathway analysis (investigating e.g., biological
processes, functional role and sub cellular localization using the
KEGG database (www.genome.jp/kegg/)), 4) interactomes (a
protein-protein interaction analysis with trans-organism protein-
protein interaction transferal) [15], and 5) the GNF expression
profiles from healthy tissues [16,17].
One interactome contained 5 of our 37 biological candidate
genes (Figure 1). Five genes – peroxisomal bifunctional enzyme
(EHHADH), enoyl-CoA hydratase, mitochondrial (ECHS1), long-
chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL),
trifunctional enzyme subunit alpha, mitochondrial (HADHA), and
trifunctional enzyme subunit beta, mitochondrial (HADHB) – were
chosen from this interactome for further investigation, based on
the following criteria: 1) centrally placed in the interactome; 2) five
or more connections to other nodes in the network; and, if
available, evidence of high levels of expression in the liver
compared to other tissues.
Selection of SNPs for genotyping
According to HapMap phase II (release 24), 21 tagSNPs (CEU)
capture all variation in these genes (610 kb) at an r
2 threshold of
at least 0.8 (MAF between 1 and 45%) and were chosen for
genotyping. Since HADHA and HADHB share chromosomal
location and therefore are tagged by the same variants, they will
from now on be referred to as HADHA/B and analyzed together.
Haploview (version 4.2) was used to construct linkage disequilib-
rium (LD) plots displaying r
2 between each genotyped variant in a
locus (Supporting Information S1).
Genotyping
The tagSNPs were genotyped using KASParH (KBiosciences,
UK) with success rates .96% and error rates not exceeding 0.5%
(.1,177 replicates). Genotype distributions obeyed Hardy-Wein-
berg equilibrium (P.0.05) in all study groups, except for
rs1056471 (P=0.05) and rs3791731 (P=0.007) in HADHA/B;
and rs6805633 (P=4 610
227)i nEHHADH. These three SNPs
were excluded from the analyses.
Study participants
This study involved 10,196 unrelated Danes from four study
groups. Details of the study samples are given in Supporting
Information S1. 1) The population-based sample (Inter99) of
middle-aged individuals (n=6,162) sampled at the Research
Centre for Prevention and Health [18]. 2) T2D patients sampled
through the out-patient clinic at Steno Diabetes Center (SDC)
(n=1,695). 3) A population-based group of middle-aged glucose-
tolerant participants recruited via SDC (n=730). Finally, the
ADDITION Denmark study (Anglo-Danish-Dutch Study of
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Primary Care) (ClinicalTrials.gov ID-no: NCT00237548 [19],
which is a population-based, high-risk screening and intervention
study for T2D in general practice (n=1,609) was included as the
fourth group. All participants in study group 1 and 3 underwent a
standard 75 g oral glucose tolerance test (OGTT). T2D and
glucose tolerance was diagnosed according to the World Health
Organization (WHO) 1999 criteria [20], and central obesity was
defined using waist-circumference ($88 cm for women and
$102 cm for men).
Quantitative trait analyses were carried out in glucose tolerant
individuals from study group 1 (n=4,567), whereas the case-
control studies of T2D and central obesity involved all four study
groups (n=10,196). Individuals with MetS were identified from
study group 1. The case-control study of MetS was defined
according to the 1998 WHO criteria [21] and involved 1,757
control individuals and 1,349 individuals with either impaired
glucose tolerance (defined as increased fasting glycaemia (IFG),
impaired glucose tolerance (IGT), screen-detected T2D (scT2D),
or T2D), or increased insulin resistance calculated using the
homeostasis model assessment of insulin resistance (HOMA-IR),
together with two or more components of MetS (dyslipidemia,
hypertension, obesity, or albuminuria). Control individuals were
defined as not having any of the components comprised in the
WHO-defined criteria of MetS.
Selection of NAFLD-related phenotypes
NAFLD-related quantitative traits that were investigated in this
study included: waist circumference, serum triglyceride, and
fasting levels of serum insulin and plasma glucose. These traits
were considered the best surrogate measures of NAFLD based on
previous studies [12,22].
Anthropometrical and biochemical measurements
Height (without shoes) and weight were measured in light
indoor clothing, and BMI was calculated as weight in kg/(height in
m)
2. Waist circumference was measured in the upright position
midway between the iliac crest and the lower costal margin [18].
Blood samples were drawn after a 12 h overnight fast. Plasma
Figure 1. Interactome from the protein-protein interaction analysis. Enlarged picture of the interactome, from which EHHADH, ECHS1,
HADHA, HADHB, and ACADL were selected for further analyses. Nodes are round if not on the list of prioritized candidate genes, and squared if on the
list. The thickness of the line represents the priority score. The thicker the line, the higher prioritized on the list of candidate genes. Dark background
color means highly expressed (above average) in liver compared to other tissues in the renormalized tissue expression data set [17]. White nodes
represent proteins with no expression data available in the renormalized data set. However, in the orginal GNF tissue data set [16], all the genes
corresponding to the white proteins have an expression level above the median for all tissues, supporting the observation that the proteins have a
relative higher expression in liver. In the upper right corner is the entire protein-protein interaction network depicted. The smaller interactome is
highlighted with a dashed circle. Cytoscape 2.6 (http://www.cytoscape.org/) was used to visualize the interactome.
doi:10.1371/journal.pone.0016542.g001
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Merck, Darmstadt, Germany) and serum insulin (excluding des-
31,32 and intact proinsulin) was measured using the Autodelfia
insulin kit (Perkin-Elmer/Wallac, Turku, Finland). Serum triglyc-
erides were analyzed using enzymatic colorimetric methods (GPO-
PAP and CHOD-PAP; Roche Molecular Biochemicals, Mann-
heim, Germany). HOMA-IR was calculated as: (fasting plasma
glucose (mmol/l) 6fasting serum insulin (pmol/l))/22.5 [23].
Statistical analyses
Analyses were performed using R version 2.10.0. P-values were
not adjusted for multiple hypothesis testing and P,0.05 was
considered significant.
Association with NAFLD-related phenotypes. Quanti-
tative trait studies were performed using a general linear model.
Data with non-normally distributed residuals (serum triglycerides
and serum insulin release) were logarithmically transformed prior
to analyses. All analyses were adjusted for age, sex, and BMI,
assuming an additive model (Padd). Effect sizes are denoted as b
that reflect a per allele effect with 95% confidence interval (CI),
and are given as actual values or percentage if logarithmically
transformed. The statistical power was estimated using 1,000
simulations and a significance threshold of 0.05. Based on the
allele frequencies of the variant and the sample size of 6,162
individuals, we have estimated the effect sizes per allele of
quantitative traits for which we had 60 and 90% statistical power,
respectively, to detect an association. Power estimates for the
quantitative trait analyses are summarized in Supporting
Information S1. A quantile–quantile (QQ) plot was generated by
plotting the observed ordered allele associations from the
quantitative trait analyses against the ordered expected
associations (Supporting Information S1).
To investigate higher order interactions between the 18 SNPs
and environmental factors we applied the software package
Bayesian Association for Multiple SNP Effects (BAMSE) [24],
that model gene-environment interactions while accounting for
multiple testing. We used the Inter99 study population including
the 18 SNPs and glucose tolerance status (NGT, IFG, IGT, and
scT2D), as well as questionnaire-based information on four self-
reported environmental factors: physical activity (passive, light or
medium, and hard or very hard), energy intake (kJ/day), alcohol
intake (gram/day), and smoking habits (daily, occasionally, ex-
smoker or never) to test if any of these associated with any of the
investigated quantitative traits.
T2D, central obesity, and MetS association analyses.
Logistic regression was used to examine differences in genotype
distribution in the case-control studies. The T2D case-control
analyses were adjusted for age, sex, and BMI. We included 2,330
T2D patients in the case-control for central obesity, why these
analyses were adjusted for age, sex, BMI, and diabetes treatment.
The MetS case-control analyses were adjusted for age and sex. The
statistical power calculations in the case-control studies were done
using CaTS, power calculations for large genetic association studies,
available at http://www.sph.umich.edu/csg/abecasis/cats/. The
statistical power to detect an OR of 1.10 was, depending on the
investigated trait, estimated to be between 48 and 99% for variants
with a MAF.20%. The statistical power for the case-control
analyses is summarized in Supporting Information S1.
Functional prediction for the variants
The potential functional effects of the variants were predicted
using Ensembl SNP Effect Predictor (http://www.ensembl.org/)
and FastSNP [25].
Results
Selection of candidate genes
Text mining identified 273 genes putatively implicated in
NAFLD-related phenotypes, of which 37 biological candidate
genes where selected for further analysis. From these genes
EHHADH, ECHS1, ACADL, HADHA, and HADHB, which are
involved in the mitochondrial fatty acid b-oxidation, were selected
as candidate genes for tagging and genotyping (Figure 1).
Studies of associations to NAFLD-related quantitative
traits
Figure 2 summarizes the results for the four NAFLD–related
quantitative traits: waist circumference, fasting serum triglyceride,
fasting plasma glucose, and fasting serum insulin; values are given
in comparable Inter99 population SD units. Nine genetic variants
showed significant associations with one or more of these traits
(Table 1). Extensive results from the quantitative association
analysis are enclosed in Supporting Information S1. A QQ-plot to
visualize the distribution of observed versus expected P-values
from the quantitative trait analyses, is enclosed in Supporting
Information S1.
Investigating higher order interactions between the 18 SNPs
and environmental factors using BAMSE showed no significant
associations.
T2D, central obesity, and MetS case-control studies
Two variants in EHHADH were associated with T2D:
rs6784193 (ORadd=1.14(1.01–1.29), Padd=0.03) and rs7635708
(ORadd=1.20(1.02–1.41), Padd=0.03). We found no association
with T2D for any of the variants in ECHS1, ACADL, or HADHA/B
(Supporting Information S1).
The minor G-allele of rs11101721 in ECHS1 associated with
central obesity (ORadd=1.21(1.05–1.40), Padd=0.008). For
HADHA/B, the minor G-allele associated with a decrease in risk of
developing central obesity (ORadd=0.93(0.87–0.99), Padd=0.03).
For the other variants, no statistically significant associations were
observed when comparing the genotype distribution between lean
individuals and obese individuals as defined by waist circumference
(Supporting Information S1).
When comparing the genotype distribution between individuals
with MetS and individuals with no clinical evidence of MetS, the
minor G-allele of rs11101721 in ECHS1 associated with MetS
(ORadd=1.20(1.01–1.43), Padd=0.04). No variants in EHHADH,
ACADL,o rHADHA/B showed associations with MetS (Supporting
Information S1).
Discussion
We aimed at identifying new putative candidate genes for
NAFLD-related phenotypes by applying trans-organism protein-
protein interaction transferal combined with liver expression data,
and to investigate genetic variants in the candidate genes and their
association with metabolic traits known to relate to NAFLD.
The main findings of this study were: 1) the bioinformatics
approach proved successful in identifying putative candidate
genes, 2) the variations in the selected candidate genes were
associated with several NAFLD-associated traits, suggesting a
potential role in the development of these metabolic phenotypes.
Selection of candidate genes
We identified five genes involved in the b-oxidation of fatty
acids. The activities of mitochondrial respiratory chain enzyme
complexes have been shown to be impaired in the liver of patients
Genetics of NAFLD-Related Metabolic Phenotypes
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play a role in the pathogenesis of NAFLD. However, it has not yet
been clarified which molecular mechanisms cause the defects. A
common denominator of the five identified genes is peroxisome
proliferator-activated receptor alpha (PPARa), which play a role in
regulation of the genes. PPARa has previously been investigated in
our study populations in relation to T2D- and obesity-related
quantitative traits [27], but has also been suggested as a gene
predisposing for NAFLD [28]. PPARa is the main regulator of
fatty acid utilization [29] and when activated, PPARa causes a
decrease in plasma-, hepatic-, and intramuscular contents of
triglycerides [30]. EHHADH binds to PPARa providing a positive
feed-back loop, thereby adjusting the tissue expression levels of
PPARa according to a given metabolic need [31]. In rats, down-
regulation of ECHS1 has been identified as a contributing factor in
high-fat diet induced hepatic steatosis, causing decreased mito-
chondrial fatty acid b-oxidation, a finding that was validated in
patients with simple steatosis [32]. Furthermore, it was shown that
down-regulation of ECHS1 by small interfering RNA (in vitro and in
vivo) aggravated the accumulation of lipids in hepatocytes caused
by free fatty acid overload [32]. Moreover, PPARa responsive
elements have been identified in ECHS1 [33], but it remains to be
Figure 2. Quantitative trait analyses of NAFLD-related traits in (n=4,567) glucose-tolerant Danes. Standardized Inter99 population SD
units for NAFLD-related traits: waist circumference, fasting serum triglycerides, fasting plasma glucose, and fasting serum insulin. Calculated as
mean(trait)/SD(trait). The analyses were adjusted for age, sex, and BMI.
doi:10.1371/journal.pone.0016542.g002
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oxidation induced by ECHS1 down-regulation is mediated
through PPARa.
PPARa agonists used to treat dyslipidemia have been shown to
moderately induce the expression of ACADL and ECHS1 in rat
liver [34], and in rat heart muscle PPARa agonists increase the
expression of ECHS1 and reduce the expression of HADHA/B
[35]. These findings may indicate that PPARa also regulates these
genes. Furthermore, treatment with a PPARa agonist improved
steatosis in fatty liver Shionogi mice and reduced hepatic
triglyceride level by inducing expression of several genes involved
in the turnover of fatty acids, e.g., ACADL [36]. In a study of 26
histology diagnosed NAFLD patients, liver expression of both
ACADL and HADHA was increased 3-6-fold compared to healthy
individuals [28]. In contrast, Eaton et al. showed that patients with
NAFLD had a significantly increased amount of 3-hydroxyacyl-
CoA and 2-enoyl-CoA esters in their liver mitochondria,
suggesting a decreased HADHA activity [37].
Investigating a potential functional role of the variants included
in this study, revealed that rs2286936 of ACADL is a non-
synonymous coding variant and thereby could impact on the
measured phenotypes. This variant has been shown to associate
with the metabolite acylcarnitine 9 in a GWA study of 163
metabolic traits measured in human blood (initial step: n=1,809/
replication step: n=422), indicating that this variant may play a
role in human lipid metabolism [38]. None of the other variants
are coding variants, but thorough functional characterization is
warranted to eliminate other mechanisms in which these variants
might alter the phenotype. Taken into account the previous
knowledge about the five selected genes, we propose that they are
reasonable candidate genes, and therefore hypothesize that they
may play a role in the development in NAFLD and NAFLD-
related metabolic traits.
The NAFLD-associated PNPLA3 was not directly identified
using this approach, but the glycerolipid metabolism pathway that
PNPLA3 is involved in, is connected to the fatty acid metabolism
pathway, which was one of the top ranked pathways in the
pathway analysis.
Association with NAFLD-associated quantitative traits
Variation in several of the genes associated with the investigated
quantitative traits that relate to NAFLD, indicating that these
genes, alone or in combination, might influence the development
and/or progression of NAFLD. However, no evidence of
associations of major effects between these variants and
NAFLD-related quantitative traits was found. We constructed a
QQ-plot to visualize the distribution of observed versus expected
P-values from the quantitative trait analyses. Limits to this method
are the low number of observations, potentially high LD between
some of the variants, and non-normally distributed data. Despite
this, the QQ-plot showed an over-abundance of low P-values
(Supporting Information S1). Given the relatively high LD
between some of the variants in a locus that shows associations
with a trait, e.g., rs6783938 and rs6784193 of EHHADH with
r
2=0.7 which both are associated with fasting serum insulin, we
cannot preclude that these associations reflect the same causative
variant. None of the investigated variants were identified in the
recent GWA studies of NAFLD or surrogate NAFLD measures
such as plasma levels of liver enzymes [13,14]. Hence, investigat-
ing the effect of these variants in combination with other genetic
variants or environmental factors would help elucidating their
potential role in NAFLD. However, examining higher order
interactions between the variants and environmental factors in the
present study applying the software package BAMSE did not show
any combinations that significantly contributed to the investigated
NAFLD-related phenotypes (data not shown).
T2D, central obesity, and MetS case-control studies
Only few of the variants showed association to T2D, MetS, or
central obesity. This is, however, not tantamount to them being
irrelevant for the development of NAFLD. Here, we assume that
individuals with T2D, MetS, or central obesity suffer from some
degree of NAFLD, but we have no clinical evidence of liver disease
in these patients. Therefore, an alternative study design would be
to focus on search for associations of these variants with the
mentioned metabolic disorders in cases with clinically diagnosed
NAFLD.
Table 1. Nominal statistically significant associations with NAFLD-related traits in the quantitative trait analyses in (n=4,567)
glucose-tolerant Danes.
Gene SNP Major/minor allele Trait
n
WT/HE/HO
Per allele effect
(95%CI) Padditive
EHHADH rs2216386 A/G Fasting serum insulin 2777/1406/180 3.4% (0.8%; 6.1%) 0.01
EHHADH rs16859825 T/C Fasting plasma glucose
(mmol/l)
3747/613/24 0.033 (0.004;0.062) 0.03
Fasting serum insulin 5.3% (1.4%;9.3%) 0.01
EHHADH rs6783938 C/T Fasting serum insulin 3596/765/39 4.1% (0.5%; 7.7%) 0.03
EHHADH rs6784193 A/G Fasting serum insulin 3089/1157/107 3.8% (0.8%; 6.7%) 0.01
EHHADH rs6779662 T/C Waist circumference (cm) 3786/542/21 20.60 (21.03; 20.17) 0.006
EHHADH rs2160815 T/A Serum triglycerides 3397/925/67 3.2% (0.3%; 6.1%) 0.03
ECHS1 rs7093778 T/C Fasting plasma glucose
(mmol/l)
840/1350/149 0.03 (0.01; 0.05) 0.002
ACADL rs1396828 T/C Waist circumference (cm) 1267/2139/974 20.3 (20.5; 20.1) 0.01
ACADL rs2286963 T/G Waist circumference (cm) 1825/1933/569 0.26 (0.04; 0.48) 0.02
Values of serum triglycerides and serum insulin were logarithmically transformed prior to statistical analyses, and their effect sizes are presented as the increase/
decrease in percent. Effect sizes and P-values shown are for an additive genetic model and are adjusted for age, sex, and BMI. WT, wild-type. HE, heterozygous. HO,
homozygous.
doi:10.1371/journal.pone.0016542.t001
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mining and the other bioinformatics approaches used take
advantage of data available from public sources, thereby
implementing many different types of studies. Many diseases that
present a similar clinical phenotype are caused by variation in
genes that are part of the same functional protein complex, where
the overlapping phenotype can be explained by variation in single
genes, or combinations of genes, making the entire protein
complex dysfunctional [15]. Also, the large well-characterized
study samples used, in most cases provide sufficient statistical
power (.80%) to detect moderate genetic effects on quantitative
surrogate measures of NAFLD (Supporting Information S1).
One could speculate that the text mining approach would
discriminate in favor of the included genes, and that previous
studies investigating the role of variation in these genes in relation
to NAFLD, contribute to their status as highly prioritized
candidate genes. This has been taken into consideration by the
subsequent protein-protein interaction analysis, where interacting
proteins were included to the list of prioritized candidates. From
the interactome, only ACADL and HADHA were present on the
prioritized list, and we therefore believe that discrimination has
been minimized.
There are additional limitations to this study. Text mining was
limited to PubMed and OMIM only and, additionally, to a limited
time-period, meaning that we may have missed important
information reported elsewhere or at a different time-point. Also,
text mining was itself limited, as it did not include full-text articles.
However, we believe that we have accounted for this by applying
the other steps in the bioinformatics approach, in which we
extracted additional unlimited information from several other
sources.
Here we investigate the impact of potential candidate genes on
surrogate measures of NAFLD. The use of surrogate measures is
experimental and should be interpreted with caution. Further-
more, it should be noted that information on alcohol consumption
within the study population is based on questionnaires, which
introduces another bias to this study, and the possibility that
excessive alcohol abuse was present in some of the investigated
individuals cannot be eliminated. Finally, substantial multiple
testing correction is needed to account for statistical type I errors.
In the present study, Bonferroni adjustments for multiple testing
negate all associations.
Using a bioinformatics approach we have identified five new
potential candidate genes for NAFLD. Our exploratory analyses
suggest that these genes may contribute to the development of
NAFLD; however, we failed to provide evidence of associations
with major effects between SNPs in these five genes and NAFLD-
related quantitative traits, T2D, central obesity, and MetS.
Supporting Information
Supporting Information S1 Summary of the number of
abstracts retrieved from PubMed using different search
phrases.
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